参考文献:[1].中国医师协会风湿免疫科医师分会风湿病相关肺血管/间质病学组. 2018中国结缔组织病相关间质性肺病诊断和治疗专家共识[J].中华内科杂志.2018,57(8):558-565.[2].赵开娅唐小葵. 系统性硬化症相关间质性肺疾病[J].世界最新医学信息文摘(电子版), 2020, 020(070):85-87.[3].Distler O, Highland KB, Gahlemann M, et al. Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease. N Engl J Med. 2019 Jun 27;380(26):2518-2528.[4].Flaherty KR, Wells AU, Cottin V, et al. INBUILD Trial Investigators. Nintedanib in progressive interstitial lung diseases: data from the whole INBUILD trial. Eur Respir J. 2022 Mar 17;59(3):2004538.[5].Raghu G, Remy-Jardin M, Richeldi L,et al.Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. 2022 May 1;205(9):e18-e47.[6].邹庆华, 路跃武, 周京国,等. 结缔组织病相关间质性肺疾病诊疗规范[J]. 中华内科杂志, 2022, 61(11):7.